title: [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
abstract: We report a case of the rechallenge of everolimus for metastatic renal cell carcinoma (RCC) after successful recovery from grade 3 interstitial lung disease (ILD). A 76-year-old man with metastatic RCC developed grade 3 ILD one month after the initiation of everolimus therapy (10 mg/day). ILD subsided in 4 months after the withdrawal of everolimus and treatment with corticosteroids. Half dose (5 mg/day) of everolimus was rechallenged for 9 months until another grade 3 ILD developed. Everolimus kept the disease under control for 13 months including the discontinuation period.
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Noriaki
authors.initials: N
authors.lastname: Utsunomiya
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kono
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Keiyu
authors.initials: K
authors.lastname: Matsumoto
authors.affiliation: The Department of Respiratory Medicine, Kobe City Medical Center General Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsumoto
authors.affiliation: The Department of Respiratory Medicine, Kobe City Medical Center General Hospital.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakagawa
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tsunemori
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Takuya
authors.initials: T
authors.lastname: Okada
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Koei
authors.initials: K
authors.lastname: Muguruma
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Mutsushi
authors.initials: M
authors.lastname: Kawakita
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D000068338:Everolimus; D017809:Fatal Outcome; D006801:Humans; D007680:Kidney Neoplasms / Q000556:secondary* / Q000628:therapy*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D012720:Severity of Illness Index; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000068338:Everolimus; D011239:Prednisolone; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus